BARRON'S By: Andrew Barry
Barron's By: Andrew Barry Lazard Capital Markets analyst William Tanner said that the US commercial opportunity for Sarepta with eteplirsen implied a stock price of $83 to $139 a share
very informative, Lazard is one of the best analyst around.
that IS old news
why do you keep posting it like it was just the other day ???
I just read it,,, was on nasdaq news .
I cannot find this anywhere. I hope you are not citing an old article from last year.
good to know..thanks.
good link..holding my shares.
great info thanks !!!